These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27565287)

  • 1. Cholinesterase Inhibitor Utilization: The Impact of Provincial Drug Policy on Discontinuation.
    Fisher A; Carney G; Bassett K; Chappell NL
    Value Health; 2016; 19(5):688-96. PubMed ID: 27565287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.
    Fisher A; Carney G; Bassett K; Dormuth CR
    Drugs Aging; 2017 Mar; 34(3):221-231. PubMed ID: 28138912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L; Shaohung S; Cuffel B; McRae T; Mark TL; Del Valle M
    J Manag Care Pharm; 2008 Jun; 14(5):451-61. PubMed ID: 18597574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.
    Kröger E; van Marum R; Souverein P; Egberts T
    Drugs Aging; 2010 Aug; 27(8):663-75. PubMed ID: 20658794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic Initiation Among Older Dementia Patients Using Cholinesterase Inhibitors: A National Retrospective Cohort Study.
    Rege S; Carnahan RM; Johnson ML; Chen H; Holmes HM; Aparasu RR
    Drugs Aging; 2021 Jun; 38(6):493-502. PubMed ID: 33763822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study.
    Herrmann N; Binder C; Dalziel W; Smyth S; Camacho F
    Drugs Aging; 2009; 26(5):403-7. PubMed ID: 19552492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study.
    Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
    Drugs Aging; 2022 Jun; 39(6):453-465. PubMed ID: 35666463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
    Dybicz SB; Keohane DJ; Erwin WG; McRae T; Shah SN
    Am J Geriatr Pharmacother; 2006 Jun; 4(2):154-60. PubMed ID: 16860262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
    Amuah JE; Hogan DB; Eliasziw M; Supina A; Beck P; Downey W; Maxwell CJ
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):670-9. PubMed ID: 20583207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease.
    Nordström P; Religa D; Wimo A; Winblad B; Eriksdotter M
    Eur Heart J; 2013 Sep; 34(33):2585-91. PubMed ID: 23735859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study.
    Gardette V; Andrieu S; Lapeyre-Mestre M; Coley N; Cantet C; Ousset PJ; Grand A; Monstastruc JL; Vellas B
    CNS Drugs; 2010 May; 24(5):431-42. PubMed ID: 20369907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of overactive bladder associated with cholinesterase inhibitors in dementia.
    Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
    J Am Geriatr Soc; 2022 Mar; 70(3):820-830. PubMed ID: 34854475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia.
    Daiello LA; Ott BR; Lapane KL; Reinert SE; Machan JT; Dore DD
    Am J Geriatr Pharmacother; 2009 Apr; 7(2):74-83. PubMed ID: 19447360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
    Lai EC; Wong MB; Iwata I; Zhang Y; Hsieh CY; Kao Yang YH; Setoguchi S
    J Am Geriatr Soc; 2015 May; 63(5):869-76. PubMed ID: 25912671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterase inhibitors in patients with diabetes mellitus and dementia: an open-cohort study of ~23 000 patients from the Swedish Dementia Registry.
    Secnik J; Schwertner E; Alvarsson M; Hammar N; Fastbom J; Winblad B; Garcia-Ptacek S; Religa D; Eriksdotter M
    BMJ Open Diabetes Res Care; 2020 Jan; 8(1):. PubMed ID: 31958305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of cholinesterase inhibitors on postoperative outcomes of older adults with dementia undergoing hip fracture surgery.
    Seitz DP; Gill SS; Gruneir A; Austin PC; Anderson G; Reimer CL; Rochon PA
    Am J Geriatr Psychiatry; 2011 Sep; 19(9):803-13. PubMed ID: 21873836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality.
    Xu H; Garcia-Ptacek S; Jönsson L; Wimo A; Nordström P; Eriksdotter M
    Neurology; 2021 Apr; 96(17):e2220-e2230. PubMed ID: 33741639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of rivastigmine use on the risk of nursing home placement in a US sample.
    Beusterien KM; Thomas SK; Gause D; Kimel M; Arcona S; Mirski D
    CNS Drugs; 2004; 18(15):1143-8. PubMed ID: 15581384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.
    Kröger E; Berkers M; Carmichael PH; Souverein P; van Marum R; Egberts T
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):373-80. PubMed ID: 23217530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study.
    Kröger E; Van Marum R; Souverein P; Carmichael PH; Egberts T
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):276-85. PubMed ID: 25652526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.